India, June 23 -- Galectin Therapeutics Inc. (GALT), a clinical-stage biotechnology company, announced that it reached alignment with the U.S. Food and Drug Administration during a recent in-person Type C meeting on the primary endpoint and regulatory path forward for Belapectin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis, and portal hypertension.
Galectin's lead investigational drug, Belapectin, is designed to potentially inhibit the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases
Galectin intends to submit the Phase 3 protocol in the third quarter of 2026 and is actively exploring strategic and financial partnership opportunities to advance Belapectin.
T...